Suppr超能文献

(-)司来吉兰治疗失代偿期帕金森病

(-)Deprenyl in the treatment of decompensated Parkinson's disease.

作者信息

Csanda E, Tárczy M, Takáts A

出版信息

J Neural Transm Suppl. 1986;22:247-52.

PMID:3097259
Abstract

Two main forms of declining motor performance are evident in Parkinson's disease: response fluctuations and "loss of benefit", i.e., the progression of the disease without "on-off" symptoms. (-)Deprenyl has a favourable beneficial effect in reducing the mild forms of response fluctuations. The addition of (-)deprenyl in such patients to the continuing substitution therapy prevents the development of more severe "on-off" manifestations. In severely disabled patients with irregular response swings or permanent akinesia the use of (-)deprenyl as an adjuvant drug cannot modify anymore the course of the disease.

摘要

帕金森病中明显存在两种主要的运动功能下降形式

反应波动和“疗效丧失”,即疾病进展但无“开-关”症状。(-)司来吉兰在减轻轻度反应波动方面具有良好的有益效果。在此类患者中,在持续替代治疗的基础上加用(-)司来吉兰可防止更严重的“开-关”表现的出现。在反应波动不规则或存在永久性运动不能的严重残疾患者中,使用(-)司来吉兰作为辅助药物已无法再改变疾病的进程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验